跳至主要内容
临床试验/NCT04500392
NCT04500392招募中不适用

High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Sedated Gastrointestinal Endoscopes in Obesity: a Randomized Multicenter Clinical Trial

RenJi Hospital3 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2021年5月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
1,000
试验地点
3
主要终点
The incidence of hypoxia

研究概览

简要总结

Hypoxia is the most common adverse event during gastrointestinal endoscopes sedated with propofol and sufentanil, especially in obese people. In the present study, high-flow nasal cannula oxygenation will be utilized in order to reduce the incidence of hypoxia among obesity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •patients undergoing gastrointestinal endoscopes
  • •age≥18 years old and ≤70 years old
  • •patients or family members signed informed consent form
  • •ASA classification I-II
  • •BMI≥ 28kg/m²

排除标准

  • •Coagulation disorders or a tendency of nose bleeding;
  • •An episode/exacerbation of congestive heart failure (CHF) that requires a change in medication, diet or hospitalization from any cause in the last 6 months;
  • •Severe aortic stenosis or mitral stenosis;
  • •Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months;
  • •Acute myocardial infarction in the last 6 months;
  • •Acute arrhythmia (including any tachycardia - or bradycardia) with the fluid of hemodynamics instability;
  • •Diagnosed chronic obstructive pulmonary disease or current other acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy);
  • •Increased intracranial pressure;
  • •ASA classification Ⅲ-Ⅳ ;
  • •Mouth, nose, or throat infection;
  • •Liver and kidney disease
  • •Fever, defined as core body temperature > 37.5℃;
  • •Pregnancy, breastfeeding or positive pregnancy test;
  • •Emergency procedure;
  • •Patients or family members refused to participate
  • •Mental disorders and people without civil capacity

研究组 & 干预措施

Control group

Active Comparator

Oxygen(up to 6L/min) supplied with a regular nasal catheter

干预措施: Regular nasal cannula (Device)

High-flow nasal cannula group

Experimental

Oxygen(up to 60L/min) supplied with high-flow nasal cannula

干预措施: High-flow nasal cannula oxygenation (Device)

结局指标

主要结局

The incidence of hypoxia

时间窗: Patients will be followed for the duration of hospital stay, an expected average of 2 hours]

(75% ≤ SpO2 \< 90% for \<60 s)

次要结局

  • The incidence of severe hypoxia(Patients will be followed for the duration of hospital stay, an expected average of 2 hours)
  • Other adverse events include other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force and HFNC supportive oxygen therapy-related adverse events.(Patients will be followed for the duration of hospital stay, an expected average of 2 hours)
  • The incidence of subclinical respiratory depression(Patients will be followed for the duration of hospital stay, an expected average of 2 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

diansan su

Vice Chair of the Department of Anesthesiology

RenJi Hospital

研究点 (3)

Loading locations...

相似试验